Home / Diabetes treatment / Type 1 evidence in 2026
Evidence hub
Is There a Cure for Type 1 Diabetes in 2026?
There is no established general cure for type 1 diabetes in 2026. Cell-replacement and islet studies have restored endogenous insulin production in selected participants, and some of those people stopped exogenous insulin during the follow-up that was reported. The cohorts are small. Rejection, recurrent autoimmunity, immunosuppression, durability, safety, and availability remain unresolved. Insulin independence is not a permanent cure.
Applicability: these are study participants under a protocol. A headline is not a treatment that can be booked from this page.
No established general cureInsulin independence is not a cureImmunosuppression still matters
Type 1 diabetes cure 2026
Type 1 diabetes is an autoimmune attack on insulin-producing beta cells. Replacing those cells can restore endogenous insulin production only if the new cells survive rejection and the same autoimmune attack. That is a different claim from a cure, from a remission, and from a clinic package.
The programs below are not interchangeable. Stem-cell-derived islets, deceased-donor islets, and gene-edited donor islets are different cell sources. A clinical trial is not a treatment you can assume is open. A registry record is not eligibility. A publication is not international access.
Last reviewed: 3 October 2026.
2026 evidence matrix
Labels are kept separate on purpose: peer-reviewed human data, clinical trial, early human proof-of-concept, investigational, and company update. A company update can be true as a company statement and still not be a peer-reviewed result.
| Program / approach | Cell source | What was reported | Patient count | Immunosuppression | Development status | What it does not prove | Source date |
|---|---|---|---|---|---|---|---|
| Zimislecel (VX-880), FORWARD | Allogeneic stem-cell-derived, fully differentiated islet cells | Among 12 full-dose participants followed at least a year, all were free of severe hypoglycemia, had HbA1c under 7%, and spent more than 70% of time in range. Ten of the 12 were not using exogenous insulin at day 365. C-peptide had been undetectable at baseline. The authors called it a small, short-term study. Analyses were interim and not prespecified. | 14 people with at least 12 months of follow-up, of whom 12 received a full dose | Yes. The reported regimen used immunosuppression. | PEER-REVIEWED HUMAN DATA CLINICAL TRIAL INVESTIGATIONAL | A general cure, a result without immunosuppression, durability past the reported year, or an approved medicine. | New England Journal of Medicine, 20 June 2025. NCT04786262. |
| Tegoprubart plus allogeneic donor islet transplantation | Islets from a deceased donor. This is not a stem-cell product. | Company report of an investigator-led pilot: all 12 adults stopped exogenous insulin. Median follow-up 8 months, longest 22 months. Most recent HbA1c under 6.5%, mean about 5.4%. No severe hypoglycemia after transplant in that report. No rejection and no new donor-specific HLA antibodies were reported by the company. | 12 adults with long-standing type 1 diabetes | Yes. Tegoprubart is an investigational anti-CD40L antibody used inside a calcineurin-inhibitor-free immunosuppression regimen. | COMPANY UPDATE INVESTIGATIONAL | That Eledon cured diabetes, that tegoprubart is a stem-cell treatment, or that immunosuppression was avoided. | Eledon announcement, 8 June 2026. Presented at the ADA Scientific Sessions, 5–9 June 2026. |
| UP421 hypoimmune donor islets | Gene-edited allogeneic donor islets, transplanted to forearm muscle | One person received no immunosuppression. The 2025 paper reported glucose-responsive C-peptide at 12 weeks and no immune response against the edited cells. A 2026 letter reports beta-cell function and no immune response against the graft through 14 months. The 2025 dose was 7.1% of a cell mass the authors associated with insulin independence. | 1 | None in this study. | PEER-REVIEWED HUMAN DATA EARLY HUMAN PROOF-OF-CONCEPT | Insulin independence, a result for other patients, or human data for a stem-cell-derived successor product. | New England Journal of Medicine article, 4 September 2025. Letter, 10 July 2026. |
| China CiPSC and E-islet reports | Lab-made islets. The index type 1 case used the participant’s own cells. Not the same as zimislecel or donor islets. | Summary only. One published type 1 case reported insulin independence from day 75 through one year, with immunosuppression. A type 2 case is a different report. A 2026 three-person type 1 series was mixed and still used immunosuppression. | 1 in the index type 1 paper. 3 in the 2026 series. | Yes in those published reports. | PEER-REVIEWED HUMAN DATA EARLY HUMAN PROOF-OF-CONCEPT | International access, a hospital package, or a cure. Trial tables are not repeated here. | Cell, 2024. Lancet Diabetes and Endocrinology, 2026. Full limits: China evidence page. |
Scroll the table sideways on a small screen. The page itself should not scroll sideways.
What zimislecel is
Zimislecel is Vertex’s allogeneic stem-cell-derived islet-cell therapy, studied as VX-880 in FORWARD (NCT04786262). The peer-reviewed report is the June 2025 New England Journal of Medicine paper, not a 2026 approval. Participants in the full-dose group received the cells into the portal vein and used immunosuppression. Ten of 12 were off exogenous insulin at one year in that interim look. The other two are part of why this cannot be described as a result for every participant.
This review did not find an approval that would make zimislecel an established treatment. A company comment in 2025 about possible later submissions is a company update. It is not a filing confirmation and it is not a license. Manufacturing limits, who is eligible, and whether immunosuppression can ever be removed are outside what that paper settles.
Type 1 diabetes cure 2026 Eledon
Eledon is developing tegoprubart, an investigational antibody against CD40 ligand. In the 2026 University of Chicago pilot, tegoprubart was part of the immunosuppression used after transplantation of allogeneic donor islets. The cells were not grown from stem cells. Calling tegoprubart a stem-cell treatment mixes two different classes.
The 8 June 2026 company announcement says all 12 participants became insulin independent, with a median follow-up of 8 months and a maximum of 22 months. That is a company report of a meeting presentation. This page did not find a peer-reviewed paper that replaces it. The company’s own release looks ahead to regulatory guidance. Guidance is not a license. «Eledon cured diabetes» is not a sentence this page will use. A funder and the company have used hopeful cure language. That language describes their goal. It is not the evidence label.
Type 1 diabetes cure without immunosuppressants
Conventional islet transplantation and the zimislecel regimen above use immunosuppression because the immune system can reject allogeneic cells, and type 1 autoimmunity can attack beta cells again. Tegoprubart changes the immunosuppression regimen. It does not remove immunosuppression.
The hypoimmune report is the row that did without it. One person received gene-edited donor islets and no immunosuppressive drugs. Through 14 months, the New England Journal of Medicine letter describes surviving beta-cell function and no immune response against that graft. The earlier paper’s dose was a fraction of the mass those authors associated with insulin independence. Insulin production was restored in the limited sense of detectable, meal-responsive C-peptide. Full insulin independence was not the result this evidence shows. One person cannot answer the question for people with type 1 diabetes as a group.
A stem-cell-derived version of that immune-evasion idea has been described by the company as a future study. This page has no peer-reviewed human results for that successor, so it stays a company update and is not given a results row.
Latest news, and what a news line cannot do
Latest news on a type 1 diabetes cure in 2026 is a stack of different documents. The peer-reviewed dates on this page are 20 June 2025 and 4 September 2025 for the two full articles, and 10 July 2026 for the hypoimmune letter. The Eledon event date is 5–9 June 2026, with the company note on 8 June 2026. A news story that says «cure» is often repeating a speaker. The speaker’s sentence still has to sit in the right column: peer-reviewed human data, clinical trial, early human proof-of-concept, investigational, or company update.
Cell therapy for type 1 diabetes, islet transplantation, and insulin-producing beta cells are the subject of these rows. They are not one product. Deceased-donor islet transplantation, stem-cell-derived islets, and gene-edited islets should not be collapsed into a single success rate.
China-specific evidence, without a second China article
Chinese stem-cell and islet studies answer a different question: what those studies showed, and whether an international patient can reach them. That question stays on the China stem-cell evidence page. Registered studies and the access limits stay on the China diabetes trials page.
The short version, so this hub is not silent: the published type 1 case used autologous induced-pluripotent-stem-cell islets in one person, with insulin independence reported from day 75 through one year while immunosuppression continued. A type 2 report is a different person and a different study. A 2026 three-person type 1 series had mixed results and still required immunosuppression. This site has no verified route that places an international patient into those protocols. Standard type 1 care in China is a third question, covered on the type 1 treatment page. Type 2 care is on the type 2 treatment page. The wider China options page is diabetes treatment in China.
Questions people ask
Is there a cure for type 1 diabetes in 2026?
No established general cure. Selected cell-replacement and islet studies have restored insulin production, and some participants stopped exogenous insulin during follow-up. That is not a permanent cure and not a result for every person with type 1 diabetes.
How close are scientists to curing type 1 diabetes?
Close enough that a few small human studies now report endogenous insulin production, and in some protocols a period of insulin independence. Not close enough to call the disease cured. Immunosuppression, durability, safety, manufacturing, and who can be treated are still open.
Can stem cells cure type 1 diabetes?
Stem-cell-derived islets are one experimental class. In the zimislecel paper, 10 of 12 full-dose participants were off exogenous insulin at one year while using immunosuppression. That paper does not call the result a cure, and it does not apply to every stem-cell advertisement.
Has anyone with type 1 diabetes become insulin-independent after cell therapy?
Yes, in defined studies. Ten of 12 full-dose zimislecel participants at day 365, all 12 people in the 2026 donor-islet tegoprubart company report, and one published autologous China case through one year. Each result has its own cell source, immunosuppression, and follow-up. None of those facts is a permanent cure.
Can type 1 diabetes cell therapy work without immunosuppressants?
The hypoimmune donor-islet study is one person, followed to 14 months, with no immunosuppression and with detectable meal-responsive C-peptide. It did not show full insulin independence. Other programs on this page still use immunosuppression.
What is Eledon doing for type 1 diabetes?
Eledon is studying tegoprubart, an investigational anti-CD40L antibody, as immunosuppression after deceased-donor islet transplantation. It is not a stem-cell therapy. The June 2026 update is a company report of 12 people, not a statement that Eledon cured diabetes.
What is zimislecel?
Zimislecel is an investigational allogeneic stem-cell-derived islet-cell therapy from Vertex, also called VX-880. The main peer-reviewed human report is the June 2025 New England Journal of Medicine paper from FORWARD, NCT04786262. It is not an approved general treatment.
Does insulin independence mean diabetes is cured?
No. Insulin independence means exogenous insulin was not being used at the time point in the report. It does not settle durability, complications, immunosuppression, or recurrent autoimmunity. Cure, remission, and insulin independence are different words.
Can international patients get experimental diabetes cell therapy in China?
This page does not show that they can. The China evidence page states what the published studies were, and the China trials page is where access and registry status belong. A paper is not an offer of care.
Sources
- Reichman and colleagues, New England Journal of Medicine, 20 June 2025. Zimislecel, NCT04786262. DOI 10.1056/NEJMoa2506549.
- Eledon Pharmaceuticals, 8 June 2026. Company announcement of the University of Chicago investigator-initiated islet study. Not a peer-reviewed paper.
- Carlsson and colleagues, New England Journal of Medicine, 4 September 2025. One-person hypoimmune donor-islet report at 12 weeks, including the 7.1% dose comparison.
- Carlsson and colleagues, New England Journal of Medicine letter, 10 July 2026. Fourteen-month follow-up. DOI 10.1056/NEJMc2604408.
- China primary reports are summarized, not re-tabulated, on the China evidence page.
Evidence check and last reviewed: 3 October 2026. This page does not enroll a trial, accept a patient, or promise insulin independence.
Check whether a research route is open
This is a records question, not enrollment. ParkMega does not decide eligibility, reserve a trial place, or promise insulin independence.